Cargando…
Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test
BACKGROUND: We evaluated the performance of single-nucleotide polymorphism (SNP) genotyping arrays OncoScan (Thermo Fisher Scientific, San Diego, CA) and Infinium CytoSNP-850K (CytoSNP; Illumina, Waltham, MA) for assessing homologous recombination deficiency (HRD) genomic instability. METHODS: DNA (...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749332/ https://www.ncbi.nlm.nih.gov/pubmed/36517748 http://dx.doi.org/10.1186/s12885-022-10197-z |
_version_ | 1784850018482520064 |
---|---|
author | Cristescu, Razvan Liu, Xiao Qiao Arreaza, Gladys Chen, Cai Albright, Andrew Qiu, Ping Marton, Matthew J. |
author_facet | Cristescu, Razvan Liu, Xiao Qiao Arreaza, Gladys Chen, Cai Albright, Andrew Qiu, Ping Marton, Matthew J. |
author_sort | Cristescu, Razvan |
collection | PubMed |
description | BACKGROUND: We evaluated the performance of single-nucleotide polymorphism (SNP) genotyping arrays OncoScan (Thermo Fisher Scientific, San Diego, CA) and Infinium CytoSNP-850K (CytoSNP; Illumina, Waltham, MA) for assessing homologous recombination deficiency (HRD) genomic instability. METHODS: DNA (pretreatment samples) across 20 tumor types was evaluated with OncoScan, CytoSNP, and the clinically validated HRD test. Copy number variation (CNV) and loss of heterozygosity (LOH) analyses were performed with ASCATv2.5.1. Aggregate HRD genomic metrics included LOH, telomeric-allelic imbalance number (TAI), and large-scale state transition (LST). Associations between BRCA mutation (BRCAm) status and the clinically validated HRD test metric (dichotomized at a clinical cut-off) were evaluated using area under the receiver operating characteristic (AUROC); Spearman ρ was calculated for continuous metrics. CNV segmentation and HRD genomic metrics were calculated (n = 120, n = 106, and n = 126 for OncoScan, CytoSNP and clinically validated HRD test, respectively). RESULTS: When assessed by SNP arrays, the genomic metric demonstrated good association with BRCAm (AUROC of HRD: OncoScan, 0.87; CytoSNP, 0.75) and the clinically validated test (cut-off, 42; AUROC of HRD: OncoScan, 0.92; CytoSNP, 0.91). The genomic metrics demonstrated good correlation with the clinically validated aggregate HRD test metric (ρ: OncoScan, 0.82; CytoSNP, 0.81) and for each component (ρ: OncoScan, 0.68 [LOH], 0.76 [TAI], and 0.78 [LST]; CytoSNP, 0.59 [LOH], 0.77 [TAI], and 0.82 [LST]). HRD assessed by SNP genotyping arrays and the clinically validated test showed good correlation. CONCLUSION: OncoScan and CytoSNP may potentially identify most HRD-positive tumors with appropriate clinically relevant cut-offs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10197-z. |
format | Online Article Text |
id | pubmed-9749332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97493322022-12-15 Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test Cristescu, Razvan Liu, Xiao Qiao Arreaza, Gladys Chen, Cai Albright, Andrew Qiu, Ping Marton, Matthew J. BMC Cancer Research BACKGROUND: We evaluated the performance of single-nucleotide polymorphism (SNP) genotyping arrays OncoScan (Thermo Fisher Scientific, San Diego, CA) and Infinium CytoSNP-850K (CytoSNP; Illumina, Waltham, MA) for assessing homologous recombination deficiency (HRD) genomic instability. METHODS: DNA (pretreatment samples) across 20 tumor types was evaluated with OncoScan, CytoSNP, and the clinically validated HRD test. Copy number variation (CNV) and loss of heterozygosity (LOH) analyses were performed with ASCATv2.5.1. Aggregate HRD genomic metrics included LOH, telomeric-allelic imbalance number (TAI), and large-scale state transition (LST). Associations between BRCA mutation (BRCAm) status and the clinically validated HRD test metric (dichotomized at a clinical cut-off) were evaluated using area under the receiver operating characteristic (AUROC); Spearman ρ was calculated for continuous metrics. CNV segmentation and HRD genomic metrics were calculated (n = 120, n = 106, and n = 126 for OncoScan, CytoSNP and clinically validated HRD test, respectively). RESULTS: When assessed by SNP arrays, the genomic metric demonstrated good association with BRCAm (AUROC of HRD: OncoScan, 0.87; CytoSNP, 0.75) and the clinically validated test (cut-off, 42; AUROC of HRD: OncoScan, 0.92; CytoSNP, 0.91). The genomic metrics demonstrated good correlation with the clinically validated aggregate HRD test metric (ρ: OncoScan, 0.82; CytoSNP, 0.81) and for each component (ρ: OncoScan, 0.68 [LOH], 0.76 [TAI], and 0.78 [LST]; CytoSNP, 0.59 [LOH], 0.77 [TAI], and 0.82 [LST]). HRD assessed by SNP genotyping arrays and the clinically validated test showed good correlation. CONCLUSION: OncoScan and CytoSNP may potentially identify most HRD-positive tumors with appropriate clinically relevant cut-offs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10197-z. BioMed Central 2022-12-14 /pmc/articles/PMC9749332/ /pubmed/36517748 http://dx.doi.org/10.1186/s12885-022-10197-z Text en © © Merck&Co., Inc., Rahway, NJ, USA and its affiliates 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cristescu, Razvan Liu, Xiao Qiao Arreaza, Gladys Chen, Cai Albright, Andrew Qiu, Ping Marton, Matthew J. Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test |
title | Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test |
title_full | Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test |
title_fullStr | Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test |
title_full_unstemmed | Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test |
title_short | Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test |
title_sort | concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749332/ https://www.ncbi.nlm.nih.gov/pubmed/36517748 http://dx.doi.org/10.1186/s12885-022-10197-z |
work_keys_str_mv | AT cristescurazvan concordancebetweensinglenucleotidepolymorphismbasedgenomicinstabilityassaysandanextgenerationsequencingbasedhomologousrecombinationdeficiencytest AT liuxiaoqiao concordancebetweensinglenucleotidepolymorphismbasedgenomicinstabilityassaysandanextgenerationsequencingbasedhomologousrecombinationdeficiencytest AT arreazagladys concordancebetweensinglenucleotidepolymorphismbasedgenomicinstabilityassaysandanextgenerationsequencingbasedhomologousrecombinationdeficiencytest AT chencai concordancebetweensinglenucleotidepolymorphismbasedgenomicinstabilityassaysandanextgenerationsequencingbasedhomologousrecombinationdeficiencytest AT albrightandrew concordancebetweensinglenucleotidepolymorphismbasedgenomicinstabilityassaysandanextgenerationsequencingbasedhomologousrecombinationdeficiencytest AT qiuping concordancebetweensinglenucleotidepolymorphismbasedgenomicinstabilityassaysandanextgenerationsequencingbasedhomologousrecombinationdeficiencytest AT martonmatthewj concordancebetweensinglenucleotidepolymorphismbasedgenomicinstabilityassaysandanextgenerationsequencingbasedhomologousrecombinationdeficiencytest |